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We previously showed that long-lasting complete remis-
sion (CR) non-Hodgkin lymphoma (NHL) patients treated
with rituximab-containing chemotherapy have an attenu-
ated antibody response to virosomal (Bedognetti et al,
J. Immunology, 2011) or MF-59 adjuvanted (Bedognetti et
al, Blood, 2012) seasonal (or pandemic) influenza vaccine
(as compared with healthy controls), associated with per-
sistent CD27+ Memory B cell depletion and hypogamma-
globulinemia. Here, we evaluated humoral and innate
response to trivalent intradermal vaccination in NHL in
CR previously treated with rituximab-containing che-
motherapy (at least one year before vaccine administra-
tion), RIT group, and in CR cancer patients treated with
chemotherapy without rituximab (at least one year before
vaccine administration), Non-RIT group. Intradermal
administration was chosen considering its promising data,
compared to conventional intramuscular route, in terms
of immunogenicity and safety. Humoral response was
assessed by hemagglutinin inhibition assay on sera col-
lected at time 0 (just before vaccination) and at time
28 (four weeks after vaccination). Innate response was
assessed by whole-genome gene expression analysis
(Affymetrix Humane Gene ST 1.0) on PBMC collected at
time 0 and at time 1 (24 hours after vaccine adminis-
tration). Patients treated with rituximab-containing che-
motherapy had, overall, a lower antibody response,
compared to patients treated with chemotherapy alone.
Overall, intradermal vaccination induced dramatic changes
in gene-expression profile already one day after vaccina-
tion. These changes underline the activation of IFN stimu-
lated genes (eg, STAT1, STAT2, CXCL10, IDO1, GBP1)
and modulation of NK-associated transcripts. In addition,
pathway and gene-enrichment analysis show that RIT and
non-RIT groups have different quantitative and qualitative
transcriptomic changes 24 hours after vaccination admin-
istration. Concordantly with antibody-titer, the innate
response was more intense in Non-RIT group compared
with RIT group.
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